NOVACYT EUR0.0667 (CDI)NOVACYT EUR0.0667 (CDI)NOVACYT EUR0.0667 (CDI)

NOVACYT EUR0.0667 (CDI)

No trades
See on Supercharts

NCYT fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Novacyt SAS is a diagnostics company, which engages in the business of developing, producing, and selling vitro and molecular diagnostic tests and products for a wide range of infectious diseases. It operates through the following segments: Primer Design, IT-IS International, and Corporate. The Primer Design segment focuses on the activities of Primer Design Ltd, which is a designer, manufacturer, and marketer of molecular real-time qPCR testing devices and reagents. The IT-IS International segment is involved in IT-IS International Ltd, a diagnostic instrument development and manufacturing company specializing in the development of PCR devices for the life sciences and food testing industry. The Corporate segment includes group central and corporate costs. The company was founded by Eric Peltier, Gerald Ulrich, and Jean-Pierre Crinelli on July 3, 2006 and is headquartered in Velizy-Villacoublay, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

NCYT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company